Citations

Showing 10 of 108119 citations.

Aquablation therapy in large prostates (80–150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3‐year trial results
Zorn, Kevin C. , Bidair, Mohamed , Trainer, Andrew, Arther, Andrew, Kramolowsky, Eugene V., Desai, Mihir , Doumanian, Leo, Elterman, Dean , Kaufman, Ronald P., Lingeman, James E., Krambeck, Amy E. , Eure, Gregg , Badlani, Gopal , Plante, Mark , Uchio, Edward , Gin, Greg , Goldenberg, S. Larry , Paterson, Ryan F. , So, Alan , Humphreys, Mitchell R. , Roehrborn, Claus G. , Kaplan, Steven A. , Motola, Jay , Bhojani, Naeem , Humphreys, Mitchell

Mayo Clinic

BJUI Compass | October 29, 2021 | Volume: 3 | Issue: 2 | Pages: 130-138

10.1002/bco2.121 | PMID 35474721 Get It

AbstractObjectiveThe objective of this study is to determine if Aquablation therapy can maintain its effectiveness in treating men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) with large‐volume (80–150 cc) prostates at 3 years.Subjects and MethodsOne hundred one men with moderate‐to‐severe BPH symptoms and prostate volumes between 80 and 150 cc were enrolled in a prospective, nonrandomized, multicenter, international clinical trial in late 2017. Baseline, procedural, and follow‐up parameters were recorded at baseline and scheduled postoperative visits. IPSS, Qmax, and treatment failure are reported at 3 years.ResultsThe mean prostate volume was 107 cc (range 80–150). Mean IPSS improved from 23.2 at baseline to 6.5 at 3 years (16.3‐point improvement, p < 0.0001). Mean IPSS quality of life improved from 4.6 at baseline to 1.1 at 3 years (improvement of 3.4 points, p < 0.0001). Maximum urinary flow increased from 8.7 to 18.5 cc/s. At 3 year follow‐up, 6% of treated patients needed BPH medication and an additional 3% required surgical retreatment for LUTS.ConclusionsThree‐year follow‐up demonstrates a sustained symptom reduction response along with low irreversible complications to Aquablation in men with LUTS due to BPH and prostates of 80–150 cc. Current treatment options available for men with prostates of this size have similar efficacy outcomes but are burdened with high rates of irreversible complications. There are now numerous clinical studies with Aquablation used in various prostates sizes, and it should be offered as an option to men with LUTS due to BPH.
Machine Learning Prediction Models for Mortality in Intensive Care Unit Patients with Lactic Acidosis
Pattharanitima, Pattharawin , Kaewput, Wisit , Qureshi, Fahad , Petnak, Tananchai , Srivali, Narat , Gembillo, Guido , O’Corragain, O.A., Chesdachai, Supavit , Vallabhajosyula, Saraschandra , Mao, Michael A. , Cheungpasitporn, Wisit , Kaewput, Wisit , Qureshi, Fahad , Petnak, Tananchai , Srivali, Narat , Gembillo, Guido , Vallabhajosyula, Saraschandra , Mao, Michael A , Dillon, John J, Cheungpasitporn, Wisit , Pattharanitima, Pattharawin , Chesdachai, Supavit , Thongprayoon, Charat , Qureshi, Fawad , Guru, Pramod , Garovic, Vesna D. , Dillon, John

Mayo Clinic

Journal of Clinical Medicine | October 28, 2021 | Volume: 10 | Issue: 21 | Pages: 5021

10.3390/jcm10215021 | PMID 34768540 Get It

Background: Lactic acidosis is the most common cause of anion gap metabolic acidosis in the intensive care unit (ICU), associated with poor outcomes including mortality. We sought to compare machine learning (ML) approaches versus logistic regression analysis for prediction of mortality in lactic acidosis patients admitted to the ICU. Methods: We used the Medical Information Mart for Intensive Care (MIMIC-III) database to identify ICU adult patients with lactic acidosis (serum lactate ≥4 mmol/L). The outcome of interest was hospital mortality. We developed prediction models using four ML approaches consisting of random forest (RF), decision tree (DT), extreme gradient boosting (XGBoost), artificial neural network (ANN), and statistical modeling with forward stepwise logistic regression using the testing dataset. We then assessed model performance using area under the receiver operating characteristic curve (AUROC), accuracy, precision, error rate, Matthews correlation coefficient (MCC), F1 score, and assessed model calibration using the Brier score, in the independent testing dataset. Results: Of 1919 lactic acidosis ICU patients, 1535 and 384 were included in the training and testing dataset, respectively. Hospital mortality was 30%. RF had the highest AUROC at 0.83, followed by logistic regression 0.81, XGBoost 0.81, ANN 0.79, and DT 0.71. In addition, RF also had the highest accuracy (0.79), MCC (0.45), F1 score (0.56), and lowest error rate (21.4%). The RF model was the most well-calibrated. The Brier score for RF, DT, XGBoost, ANN, and multivariable logistic regression was 0.15, 0.19, 0.18, 0.19, and 0.16, respectively. The RF model outperformed multivariable logistic regression model, SOFA score (AUROC 0.74), SAP II score (AUROC 0.77), and Charlson score (AUROC 0.69). Conclusion: The ML prediction model using RF algorithm provided the highest predictive performance for hospital mortality among ICU patient with lactic acidosis.
Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer
Kyprianou, Natasha , Lucien, Fabrice , Lucien, Fabrice

Mayo Clinic

International Journal of Molecular Sciences | October 28, 2021 | Volume: 22 | Issue: 21 | Pages: 11645

10.3390/ijms222111645 | PMID 34769075 Get It

This Special Issue focuses on the molecular mechanisms involved in therapeutic resistance, lineage plasticity, and phenotypic reprogramming leading to prostate cancer recurrence and, ultimately, lethal disease [...]
Retinal Venular Tortuosity Jointly with Retinal Amyloid Burden Correlates with Verbal Memory Loss: A Pilot Study
Dumitrascu, Oana M. , Rosenberry, Ryan , Sherman, Dale , Khansari, Maziyar M. , Sheyn, Julia, Torbati, Tania , Sherzai, Ayesha , Sherzai, Dean , Johnson, Kenneth O., Czeszynski, Alan , Verdooner, Steven, Black, Keith L. , Frautschy, Sally A. , Lyden, Patrick D. , Shi, Yonggang , Cheng, Susan , Koronyo, Yosef, Koronyo‐Hamaoui, Maya , Dumitrascu, Oana M , Johnson, Kenneth O., Black, Keith L

Mayo Clinic

Cells | October 28, 2021 | Volume: 10 | Issue: 11 | Pages: 2926

10.3390/cells10112926 | PMID 34831149 Get It

Introduction: Retinal imaging is a non-invasive tool to study both retinal vasculature and neurodegeneration. In this exploratory retinal curcumin-fluorescence imaging (RFI) study, we sought to determine whether retinal vascular features combined with retinal amyloid burden correlate with the neurocognitive status. Methods: We used quantitative RFI in a cohort of patients with cognitive impairment to automatically compute retinal amyloid burden. Retinal blood vessels were segmented, and the vessel tortuosity index (VTI), inflection index, and branching angle were quantified. We assessed the correlations between retinal vascular and amyloid parameters, and cognitive domain Z-scores using linear regression models. Results: Thirty-four subjects were enrolled and twenty-nine (55% female, mean age 64 ± 6 years) were included in the combined retinal amyloid and vascular analysis. Eleven subjects had normal cognition and 18 had impaired cognition. Retinal VTI was discriminated among cognitive scores. The combined proximal mid-periphery amyloid count and venous VTI index exhibited significant differences between cognitively impaired and cognitively normal subjects (0.49 ± 1.1 vs. 0.91 ± 1.4, p = 0.006), and correlated with both the Wechsler Memory Scale-IV and SF-36 mental component score Z-scores (p < 0.05). Conclusion: This pilot study showed that retinal venular VTI combined with the proximal mid-periphery amyloid count could predict verbal memory loss. Future research is needed to finesse the clinical application of this retinal imaging-based technology.
Echocardiographic Correlates of Mortality Among Cardiac Intensive Care Unit Patients With Cardiogenic Shock
Jentzer, Jacob C., Tabi, Meir, Wiley, Brandon M., Singam, Narayana S. V., Anavekar, Nandan S., Singam, Narayana Sarma V. , Singam, N Sarma V , Jentzer, Jacob C., Tabi, Meir, Wiley, Brandon M., Anavekar, Nandan S.

Mayo Clinic

Shock | October 28, 2021 | Volume: 57 | Issue: 3 | Pages: 336-343

10.1097/shk.0000000000001877 | PMID 34710882 Get It

ABSTRACT Background: Prior studies have shown worse outcomes in patients with cardiogenic shock (CS) who have reduced left ventricular ejection fraction (LVEF), but the association between other transthoracic echocardiogram (TTE) findings and mortality in CS patients remains uncertain. We hypothesized that Doppler TTE measurements would outperform LVEF for risk stratification. Methods: Retrospective analysis of cardiac intensive care unit patients with an admission diagnosis of CS and a TTE within 1 day of admission. Hospital survivors and inpatient deaths were compared, and multivariable logistic regression was used to analyze the associations between TTE variables and hospital mortality. Results: We included 1,085 patients, with a median age of 69.5 (59.6, 77.5) years; 37% were females and 62% had an acute coronary syndrome. Most patients (66%) had moderate or severe left ventricular (LV) systolic dysfunction, and 48% had moderate or severe right ventricular (RV) systolic dysfunction. Hospital mortality occurred in 31%, and inpatient deaths had a lower median LVEF (29% vs. 35%, P < 0.001). Patients with mild or no LV or RV dysfunction were at lower risk of adjusted hospital mortality (P < 0.01). The LV outflow tract (LVOT) velocity-time integral (VTI) was the single best predictor of hospital mortality. After multivariable adjustment, both the LVEF and LVOT VTI remained strongly associated with hospital mortality (P < 0.001). Conclusions: Early comprehensive Doppler TTE can provide important prognostic insights in CS patients, highlighting its potential utility in clinical practice. The LVOT VTI, reflecting forward flow, is an important measurement to obtain on bedside TTE.
Nanoparticle-Enabled Multiplexed Electrochemical Immunoassay for Detection of Surface Proteins on Extracellular Vesicles
Lee, Seonhwa , Verkhoturov, Stanislav V. , Verkhoturov, Dmitriy S., Eller, Michael J. , Revzin, Alexander , Crulhas, Bruno P. , Eller, Michael J , Schweikert, Emile A , Revzin, Alexander , Šuvakov, Sonja , Malhi, Harmeet , Garovic, Vesna D. , Stybayeva, Gulnaz

Mayo Clinic

ACS Applied Materials & Interfaces | October 28, 2021 | Volume: 13 | Issue: 44 | Pages: 52321-52332

10.1021/acsami.1c14506 | PMID 34709783 Get It

Coronavirus Disease 2019 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida Through August 2021
Bosch, Wendelyn , Cowart, Jennifer B. , Bhakta, Shivang , Carter, Rickey E. , Wadei, Hani M. , Shah, Sadia , Sanghavi, Devang , Pollock, Benjamin D. , Neville, Matthew R., Oman, Sven P. , Speicher, Leigh L. , Scindia, Ameya D., Matson, Mark W., Shah, Sadia Z. , Sanghavi, Devang K., Speicher, Leigh, Moreno Franco, Pablo, Carter, Rickey E , Wadei, Hani M , Pollock, Benjamin D , Franco, Pablo Moreno

Mayo Clinic

Clinical Infectious Diseases | October 28, 2021 | Volume: 75 | Issue: 1 | Pages: e892-e894

10.1093/cid/ciab932 | PMID 34726700 Get It

Abstract We characterized coronavirus disease 2019 (COVID-19) breakthrough cases admitted to a single center in Florida. With the emergence of delta variant, an increased number of hospitalizations was seen due to breakthrough infections. These patients were older and more likely to have comorbidities. Preventive measures should be maintained even after vaccination.
Prognostic significance of acquired 1q22 gain in multiple myeloma
Audil, Hadiyah Y. , Cook, Joselle , Greipp, Patricia T. , Kapoor, Prashant , Gertz, Morie A. , Lacy, Martha Q. , Dingli, David , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Siddiqui, Mustaqeem , Hwa, Yi L. , Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Cook, Joselle M , Dispenzieri, Angela , Gertz, Morie A , Fonder, Amie L, Muchtar, E , Gonsalves, Wilson , Hwa, Yi L , Leung, Nelson , Kourelis, Taxiarchis , Warsame, Rahma , Rajkumar, S Vincent , Kumar, Shaji K , Siddiqui, Mustaqeem A , Dingli, David , Greipp, Patricia T , Lin, Yi , Audil, Hadiyah Yasin , Baughn, Linda B. , Dispenzieri, Angela , Buadi, Francis K. , Muchtar, Eli , Gonsalves, Wilson I. , Leung, Nelson , Ketterling, Rhett P. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | October 28, 2021 | Volume: 97 | Issue: 1 | Pages: 52-59

10.1002/ajh.26391 | PMID 34710241 Get It

AbstractGain of 1q22 at diagnosis portends poorer outcomes in multiple myeloma (MM), but the prognostic significance of acquired 1q22 gain is unknown. We identified 63 MM patients seen at Mayo Clinic from 1/2004 to 12/2019 without 1q22 gain at diagnosis who acquired it during follow up and compared them to 63 control patients who did not acquire 1q22 gain with similar follow up. We also compared outcomes in the acquired 1q22 gain group with outcomes in 126 patients with 1q22 gain present at diagnosis. The incidence of acquired 1q22 gain was 6.1% (median follow‐up 6.8 years); median time to acquisition was 5.0 years (range: 0.7–11.5 years). Abnormalities on baseline fluorescence in situ hybridization (FISH) included trisomies (54%) and monosomy 13 (39%); 16 (25%) had high‐risk (HR) translocations or del(17p). Median progression‐free survival with front line therapy was 29.5 months in patients with acquired 1q22 gain, versus 31.4 months in control patients (p = .34) and 31.2 months in patients with de novo 1q22 gain (p = .04). Median overall survival (OS) from diagnosis was 10.9 years in patients with acquired 1q22 gain, versus 13.0 years in control patients (p = .03) and 6.3 years in patients with de novo 1q22 gain (p = .01). Presence of HR FISH at baseline increased risk of 1q22 gain acquisition. We demonstrate that acquisition of 1q22 gain is a significant molecular event in MM, associated with reduced OS. Among HR patients for whom this clonal evolution is determined, a risk‐adapted approach and/or clinical trial should be considered.
Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia
Rashkovan, Marissa , Alberó, Robert , Gianni, Francesca, Perez-Duran, Pablo, Miller, Hannah I. , Mackey, Adam L. , Paietta, Elisabeth M., Tallman, Martin S., Rowe, Jacob M., Litzow, Mark R., Wiernik, Peter H., Luger, Selina, Sulis, Maria Luisa, Ferrando, Adolfo A., Soni, Rajesh K , Rashkovan, Marissa , Albero, Robert , Gianni, Francesca , Perez-Duran, Pablo, Miller, Hannah I. , Mackey, Adam L. , Paietta, Elisabeth M., Tallman, Martin S., Rowe, Jacob M., Litzow, Mark R., Wiernik, Peter H., Luger, Selina, Sulis, Maria Luisa, Ferrando, Adolfo A.

Mayo Clinic

Cancer Discovery | October 28, 2021 | Volume: 12 | Issue: 3 | Pages: 856-871

10.1158/2159-8290.cd-21-0551 | PMID 34711640 Get It

Abstract Early T-cell acute lymphoblastic leukemia (ETP-ALL) is an aggressive hematologic malignancy associated with early relapse and poor prognosis that is genetically, immunophenotypically, and transcriptionally distinct from more mature T-cell acute lymphoblastic leukemia (T-ALL) tumors. Here, we leveraged global metabolomic and transcriptomic profiling of primary ETP- and T-ALL leukemia samples to identify specific metabolic circuitries differentially active in this high-risk leukemia group. ETP-ALLs showed increased biosynthesis of phospholipids and sphingolipids and were specifically sensitive to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase, the rate-limiting enzyme in the mevalonate pathway. Mechanistically, inhibition of cholesterol synthesis inhibited oncogenic AKT1 signaling and suppressed MYC expression via loss of chromatin accessibility at a leukemia stem cell–specific long-range MYC enhancer. In all, these results identify the mevalonate pathway as a druggable novel vulnerability in high-risk ETP-ALL cells and uncover an unanticipated critical role for cholesterol biosynthesis in signal transduction and epigenetic circuitries driving leukemia cell growth and survival. Significance: Overtly distinct cell metabolic pathways operate in ETP- and T-ALL pointing to specific metabolic vulnerabilities. Inhibition of mevalonate biosynthesis selectively blocks oncogenic AKT–MYC signaling in ETP-ALL and suppresses leukemia cell growth. Ultimately, these results will inform the development of novel tailored and more effective treatments for patients with high-risk ETP-ALL. This article is highlighted in the In This Issue feature, p. 587
Review: Long-acting insulin analogues do not improve glycemic control but do reduce nocturnal hypoglycemia in diabetes
Smith, Steven A., Murad, M. Hassan

Mayo Clinic

ACP Journal Club | October 28, 2021 | Volume: 148 | Issue: 2 | Pages: 37

10.7326/acpjc-2008-148-2-037 | PMID 18311867 Get It